FICAN Science webinar: Development of patient-derived models and molecular biomarkers for improved risk assessment and prediction of drug response in bladder cancer
Published 17.11.2026
These nationwide webinars aim to share information about cancer research and its results conducted in various regions and foster collaboration and discussion for the benefit of cancer patients throughout Finland.

09.12 @ 15:00 – 16:00

Time: Wed 9.12 klo 15-16
Topic: Development of patient-derived models and molecular biomarkers for improved risk assessment and prediction of drug response in bladder cancer
Speaker: Professor Pekka Taimen
Institute of Biomedicine, University of Turku and Department of Pathology, Turku University Hospital
Get to know the Speaker: www.taimenlab.fi
The webinar is organized by FICAN West.
You can join the webinar directly from this link: Join the meeting
Abstract
Pekka Taimen, MD, PhD, is Professor of Molecular Pathology at the Institute of Biomedicine, University of Turku, and Chief Physician at the Department of Pathology, Turku University Hospital. His translational pathology research group focuses on biomarkers, steroidomics, and patient-derived cell culture models of bladder cancer. Their research on prostate cancer aims to improve diagnostic accuracy and risk stratification by integrating MRI/PET imaging with histopathological data, while lung cancer research has focused on cancer genomics and predictive biomarkers. In addition, Taimen’s laboratory investigates the pathobiology of familial cardiomyopathy caused by pathogenic variants in the LMNA gene, which encodes the nuclear intermediate filament proteins known as lamins.
In this webinar, Taimen will present their recent advances in bladder cancer research, including the development of patient-derived cell culture models for drug sensitivity testing, as well as projects involving steroid hormone and transcriptomic profiling.
Relevant references for this talk:
- Saarikoski K, Askari A, Erkkilä S, Keski-Oja T, Vainio P, Nurminen A, Lamminen T, Suhonen J, Rantala JK, Boström PJ, Kettunen K, Taimen P, Turku Prostate Cancer Consortium (2026). Patient-derived conditionally reprogrammed cells for bladder cancer modeling and drug sensitivity assessment. npj Precision Oncology, in press.
- Askari A, Mahmoudian M, Lamminen T, Heuser V, Koskinen I, Mirtti T, Elo LL, Schleutker J, Taimen P, Boström PJ (2026). Prediction of platinum-based neoadjuvant chemotherapy response in muscle-invasive bladder cancer using a multifaceted approach. Scientific Reports, 16:36990. https://doi.org/10.1038/s41598-026-64713-3
- Kettunen K, Mathlin J, Lamminen T, Laiho A, Häkkinen MR, Auriola S, Elo LL, Boström PJ, Poutanen M, Taimen P (2024). Profiling steroid hormone landscape of bladder cancer reveals depletion of intratumoural androgens to castration levels: a cross-sectional study. eBioMedicine 108:105359. https://10.1016/j.ebiom.2024.105359
- Kettunen K, Boström PJ, Lamminen T, Heinosalo T, West G, Saarinen I, Kaipio K, Rantala J, Albanese C, Poutanen M, Taimen P (2019). Personalized drug sensitivity screening for bladder cancer using conditionally reprogrammed patient-derived cells. European Urology 76:430-434. https://doi.org/10.1016/j.eururo.2019.06.016
